#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6486	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2177	571.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1636	1636	T	688	T,G,C	419,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6486	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2177	571.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1370	1370	C	825	C,G,T	511,4,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12162	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3346	671.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1551	1551	A	691	A	440	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12162	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3346	671.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2185	2185	C	625	C,A	395,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12162	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3346	671.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2811	2811	T	677	T,G,C	453,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12162	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3346	671.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2259	2259	A	669	A,C	421,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	480	folP	855	855	100.0	folP.l15.c4.ctg.1	1845	53.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1128	1130	AGC	74;76;78	A,T;G,A;C,G	49,1;50,1;52,1	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1394	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3480	76.0	1	SNP	p	S91F	1	.	.	271	273	TTC	594	596	TTC	92;93;93	T;T,A;C,T	61;59,1;59,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1394	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3480	76.0	1	SNP	p	G95N	0	.	.	283	285	GGC	606	608	GGC	104;104;104	G;G,A;C	67;66,1;66	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1394	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3480	76.0	1	SNP	p	D95G	1	.	.	283	285	GGC	606	608	GGC	104;104;104	G;G,A;C	67;66,1;66	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	394	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1169	69.5	1	SNP	p	G45D	0	.	.	133	135	GGC	460	462	GGC	102;102;102	G;G;C	63;62;65	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	298	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1039	52.3	0	.	n	.	0	A197.	DEL	197	197	A	641	641	A	123	A	79	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1110	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2823	74.7	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1357	1359	GTC	61;58;58	G;T,G;C	37;37,2;39	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1110	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2823	74.7	1	SNP	p	D86N	0	.	.	256	258	GAC	463	465	GAC	98;96;98	G;A,T;C,T	58;56,1;61,1	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1110	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2823	74.7	1	SNP	p	R87I	0	.	.	259	261	CGT	466	468	CGT	98;98;99	C;G;T	66;61;61	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1110	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2823	74.7	1	SNP	p	R87W	0	.	.	259	261	CGT	466	468	CGT	98;98;99	C;G;T	66;61;61	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1110	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2823	74.7	1	SNP	p	S87R	1	.	.	259	261	CGT	466	468	CGT	98;98;99	C;G;T	66;61;61	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1110	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2823	74.7	1	SNP	p	S88P	0	.	.	262	264	TCC	469	471	TCC	99;99;99	T;C,T;C	62;63,1;66	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	928	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2621	69.8	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1299	1301	TGC	87;87;87	T;G;C	56;54;56	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	928	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2621	69.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1509	1511	GGC	64;65;66	G;G;C	45;43;42	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1119	1121	GCA	166;166;165	G;C;A	106;106;105	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1122	1124	ATC	167;167;166	A;T;C	106;107;106	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1134	1136	GTG	163;160;160	G;T,G;G	105;100,2;102	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1134	1136	GTG	163;160;160	G;T,G;G	105;100,2;102	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1638	1640	ACC	83;84;82	A;C;C,G	50;57;55,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1692	1694	GCG	65;64;64	G;C;G	48;46;47	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1692	1694	GCG	65;64;64	G;C;G	48;46;47	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1815	1817	GGC	60;60;60	G;G;C	45;45;45	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1824	1826	GGC	51;50;50	G;G;C	39;36;33	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2120	107.7	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1842	1844	TCG	56;56;56	T,G;C;G	34,2;38;39	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	2102	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2830	133.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1437	1439	CCG	86;86;87	C;C;G	56;57;54	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	600	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1987	58.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	553	553	C	59	C	33	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	902	904	AAT	12;12;12	A;A;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	905	907	AAT	12;12;11	A;A;T	8;8;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	929	931	GCA	10;10;10	G;C;A	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	952	954	GTA	10;10;10	G;T;A	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	S236N	NONSYN	706	708	AGC	958	960	AAC	10;10;10	A;A;C	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	.	MULTIPLE	709	711	AAC	962	966	TGGCG	10;9;9;9;9	T;G;G;C;G	6;5;5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	D238A	NONSYN	712	714	GAT	968	970	GCT	9;9;9	G;C;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1028	1030	TTA	8;8;8	T;T;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	Y273R	NONSYN	817	819	TAT	1073	1075	CGT	7;7;7	C;G;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1076	1078	AGT	7;7;7	A;G;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	66	porB1a	984	297	90.03	porB1a.l15.c4.ctg.1	1176	10.7	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1085	1087	TAC	7;7;7	T;A;C	4;4;4	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	724	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1590	87.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	464	466	GAA	147;142;142	G,A;A,C;A	90,2;89,1;90	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	724	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1590	87.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	752	754	GAT	80;88;88	G;A,G;T,C,A	58;59,1;56,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	724	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1590	87.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	875	877	TCA	104;104;104	T;C,A;A,T	71;69,2;71,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	724	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1590	87.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1004	1006	GTC	113;111;112	G;T;C	79;78;78	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	724	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1590	87.0	0	.	p	.	0	H294R	NONSYN	880	882	CAT	1232	1234	CGT	131;132;132	C;G,T;T	84;83,1;83	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	724	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1590	87.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1334	1336	GCA	100;100;96	G;C;A,G	67;67;63,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	724	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1590	87.0	1	SNP	p	G120K	1	.	.	358	360	AAG	710	712	AAG	90;90;90	A,T;A,G;G	62,1;62,1;64	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	724	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1590	87.0	1	SNP	p	D121N	0	.	.	361	363	GAC	713	715	GAC	91;89;88	G;A;C	65;64;63	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	724	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1590	87.0	1	SNP	p	A121D	1	.	.	361	363	GAC	713	715	GAC	91;89;88	G;A;C	65;64;63	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2666	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4715	108.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2016	2018	AAT	115;116;116	A;A;T	77;78;78	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	228	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1021	45.0	1	SNP	p	V57M	1	.	.	169	171	ATG	530	532	ATG	80;77;78	A;T;G	55;53;54	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
